Using data from 136 patients, the researchers built a model based on 10 key variables—including tumor sidedness and several routine blood biomarkers such as ferritin, CA19-9, and CRP—to predict which patients are more likely to experience longer periods without disease progression. Here, CRP is linked to neoplasm.